Generalized myasthenia gravis (gMG) necessitates nuanced, individualized care for optimal management. Neonatal Fc receptor (FcRn) antagonists are a novel class of targeted therapies, providing a highly specific, effective treatment option for patients in need. FcRn antagonists are poised to enhance the gMG treatment landscape with a recent approval and several therapies soon to complete phase 3 trials. In this second of two videos, join two experts in an engaging discussion focusing on the individualized treatment of gMG with a closer look at patient selection for FcRn antagonism, best practices for proper monitoring and therapy adjustments, and how to engage patients with gMG using effective patient education and shared decision-making strategies. You will also gain immediate access to downloadable evidence and a concise, point-of-care resource to reference in your daily practice. This activity is delivered in partnership with the Muscular Dystrophy Association (MDA).
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/addressing-unmet-needs-gmg-enhanced-disease-recognition-therapeutic
- Start Date: 2024-08-29 05:00:00
- End Date: 2024-08-29 05:00:00
- Credit Details: IPCE Credits: 0.5 hours
AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - Commercial Support: Source: Janssen (Any division) - Amount: 62500.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all